Robert W. Baird Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price

Key Points

• Robert W. Baird has lowered its target price for Karyopharm Therapeutics from $25 to $21, maintaining an "outperform" rating that implies a potential upside of 280.09% from the current stock price.
• Other brokerages have shown mixed sentiments, with HC Wainwright downgrading KPTI from "buy" to "neutral" and Weiss Ratings issuing a "sell" rating, resulting in an average rating of "Moderate Buy" overall.
• Karyopharm recently reported a quarterly earnings miss, posting ($4.32) earnings per share against analysts' expectations of ($3.80), alongside a revenue of $37.93 million, slightly below the forecasted $37.92 million.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) had its target price decreased by equities researchers at Robert W. Baird from $25.00 to $21.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Robert W. Baird's price target would suggest a potential upside of 280.09% from the stock's current price.

A number of other brokerages have also weighed in on KPTI. HC Wainwright lowered Karyopharm Therapeutics from a "buy" rating to a "neutral" rating in a report on Wednesday, July 16th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Karyopharm Therapeutics in a report on Wednesday. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Karyopharm Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $33.20.

Karyopharm Therapeutics Trading Down 4.2%

KPTI opened at $5.53 on Thursday. The stock has a fifty day moving average price of $5.93 and a 200-day moving average price of $5.16. Karyopharm Therapeutics has a 12 month low of $3.51 and a 12 month high of $16.95. The firm has a market cap of $47.90 million, a price-to-earnings ratio of -0.38 and a beta of 0.34.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($4.32) earnings per share for the quarter, missing analysts' consensus estimates of ($3.80) by ($0.52). The firm had revenue of $37.93 million during the quarter, compared to analysts' expectations of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. On average, equities research analysts forecast that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KPTI. Baird Financial Group Inc. acquired a new stake in Karyopharm Therapeutics during the second quarter worth about $45,000. XTX Topco Ltd purchased a new position in shares of Karyopharm Therapeutics in the second quarter valued at approximately $56,000. Two Sigma Investments LP increased its holdings in Karyopharm Therapeutics by 60.3% during the 4th quarter. Two Sigma Investments LP now owns 137,786 shares of the company's stock worth $93,000 after purchasing an additional 51,856 shares during the period. Bridgeway Capital Management LLC acquired a new stake in Karyopharm Therapeutics in the second quarter valued at approximately $163,000. Finally, Silverback Asset Management LLC raised its stake in Karyopharm Therapeutics by 40.0% in the second quarter. Silverback Asset Management LLC now owns 70,000 shares of the company's stock valued at $302,000 after buying an additional 20,000 shares in the last quarter. 66.44% of the stock is currently owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.